Contribution of N-Glucuronidation to Efavirenz EliminationIn Vivoin the Basal and Rifampin-Induced Metabolism of Efavirenz
- 1 April 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (4) , 1504-1509
Abstract
In this study, the contribution of efavirenz N-glucuronidation to efavirenz eliminationin vivowas assessed. In a two-period placebo-controlled crossover trial design, a single 600-mg oral dose of efavirenz was administered to healthy volunteers (n= 10) pretreated with placebo pills or 600 mg/day rifampin orally for 10 days. Urine and plasma concentrations of efavirenz and 8-hydroxyefavirenz were measured by the liquid chromatography-tandem mass spectrometry method after enzymatic hydrolysis with β-glucuronidase (conjugated and unconjugated) and without enzymatic hydrolysis (unconjugated). Pharmacokinetic parameters of efavirenz within the placebo- or rifampin-treated group obtained after enzymatic hydrolysis did not show any statistically significant difference compared with those obtained without enzymatic hydrolysis (P> 0.05; pairedttest, two-tailed). The amount of efavirenz excreted over 12 h was significantly larger after enzymatic hydrolysis in both the placebo (P= 0.007) and rifampin (P= 0.0001) treatment groups, supporting the occurrence of direct N-glucuronidation of efavirenz, but the relevance of this finding is limited because the amount of efavirenz excreted as unchanged or conjugated in urine is less than 1% of the dose administered. In both the placebo- and rifampin-treated groups, plasma concentrations of 8-hydroxyefavirenz and the amount excreted over 12 h were significantly larger (P< 0.00001) after enzymatic hydrolysis than without enzymatic hydrolysis. These findings suggest that although the occurrence of direct efavirenz N-glucuronidation is supported by the urine data, the abundance of efavirenzN-glucuronide in plasma is negligible and that the contribution of the N-glucuronidation pathway to the overall clearance of efavirenz seems minimal.Keywords
This publication has 29 references indexed in Scilit:
- Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-HydroxylationDrug Metabolism and Disposition, 2010
- REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERSDrug Metabolism and Disposition, 2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human HepatocytesDrug Metabolism and Disposition, 2003
- Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infectionClinical Pharmacology & Therapeutics, 2003
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Rifampin Is a Selective, Pleiotropic Inducer of Drug Metabolism Genes in Human Hepatocytes: Studies with cDNA and Oligonucleotide Expression ArraysThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsAIDS, 2001
- The Species-Dependent Metabolism of Efavirenz Produces a Nephrotoxic Glutathione Conjugate in RatsToxicology and Applied Pharmacology, 2000
- Identification and Characterization of Efavirenz Metabolites by Liquid Chromatography/Mass Spectrometry and High Field NMR: Species Differences in the Metabolism of EfavirenzDrug Metabolism and Disposition, 1999